Positivity and prevalence of human papillomavirus among a large population of women in southeastern China

被引:7
作者
Liu, Sudong [1 ,2 ,3 ]
Gu, Xiaodong [1 ,2 ,3 ]
Weng, Ruiqiang [1 ,2 ,3 ]
Liu, Jing [1 ,2 ,3 ]
Zhong, Zhixiong [1 ,2 ,3 ,4 ]
机构
[1] Sun Yat Sen Univ, Meizhou Hosp, Clin Core Lab, Meizhou Peoples Hosp,Huangtang Hosp, Meizhou, Peoples R China
[2] Guangdong Prov Engn & Technol Res Ctr Mol Diagnos, Meizhou, Peoples R China
[3] Guangdong Prov Key Lab Precis Med & Clin Translat, Meizhou, Peoples R China
[4] Sun Yat Sen Univ, Meizhou Hosp, Huangtang Hosp, Meizhou Peoples Hosp,Ctr Cardiovasc Dis, Meizhou, Peoples R China
关键词
Human papillomavirus; cervical cancer; prevalence; genotypes; prevention; China; CERVICAL HUMAN-PAPILLOMAVIRUS; QUADRIVALENT VACCINE; HPV INFECTION; LOW-RISK; CANCER; EFFICACY; PROVINCE; LESIONS; BURDEN; DNA;
D O I
10.1177/0300060519870918
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective To formulate strategies for prevention of cervical cancer, we investigated the prevalence of human papillomavirus (HPV) infection and the age-specific distribution among female participants in southeastern China. Methods From January 2016 to July 2018, 36,871 women from Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University were enrolled in this prospective study. HPV genotypes were detected using Luminex technology. Results HPV infection was observed in 18.34% of the participants, and 79.98% were infected with high-risk HPVs. The five most prevalent genotypes were HPV52 (18.18%), HPV16 (16.06%), HPV58 (11.37%), HPV53 (8.82%), and HPV39 (6.42%). The 9-valent HPV vaccine efficiently reduced the HPV infection rate by more than 10%, which is twofold the rate of other vaccines. Most HPV infections were observed in women age 40 to 49 years, and those age 30 to 59 years accounted for 79.62% of positive patients. Conclusion Our findings regarding HPV genotypes and the age-specific distribution of HPV infection in the study area will contribute to the development of cervical cancer screening programs and vaccine strategies.
引用
收藏
页码:6171 / 6181
页数:11
相关论文
共 44 条
[1]   Screening-preventable cervical cancer risks:: Evidence from a nationwide audit in Sweden [J].
Andrae, Bengt ;
Kemetli, Levent ;
Sparen, Par ;
Silfverdal, Lena ;
Strander, Bjorn ;
Ryd, Walter ;
Dillner, Joakim ;
Tornberg, Sven .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (09) :622-629
[2]   Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations [J].
不详 .
VACCINE, 2015, 33 (36) :4383-4384
[3]  
[Anonymous], J NANOMATERIALS, DOI DOI 10.1155/2016/5639129
[4]   Worldwide burden of cervical cancer in 2008 [J].
Arbyn, M. ;
Castellsague, X. ;
de Sanjose, S. ;
Bruni, L. ;
Saraiya, M. ;
Bray, F. ;
Ferlay, J. .
ANNALS OF ONCOLOGY, 2011, 22 (12) :2675-2686
[5]   Are 20 human papillomavirus types causing cervical cancer? [J].
Arbyn, Marc ;
Tommasino, Massimo ;
Depuydt, Christophe ;
Dillner, Joakim .
JOURNAL OF PATHOLOGY, 2014, 234 (04) :431-435
[6]  
BOUVARD V, 2009, LANCET ONCOL, V10, P321, DOI DOI 10.1016/S1470-2045(09)70096-8
[7]   Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine [J].
Brown, DR ;
Fife, KH ;
Wheeler, CM ;
Koutsky, LA ;
Lupinacci, LM ;
Railkar, R ;
Suhr, G ;
Barr, E ;
Dicello, A ;
Li, WL ;
Smith, JF ;
Tadesse, A ;
Jansen, KU .
VACCINE, 2004, 22 (21-22) :2936-2942
[8]   Human Papillomavirus Laboratory Testing: the Changing Paradigm [J].
Burd, Eileen M. .
CLINICAL MICROBIOLOGY REVIEWS, 2016, 29 (02) :291-319
[9]   Human papillomavirus genome variants and head and neck cancers: a perspective [J].
Combes, Jean-Damien ;
Franceschi, Silvia .
INFECTIOUS AGENTS AND CANCER, 2018, 13
[10]   Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:: a meta-analysis [J].
de Sanjose, Silvia ;
Diaz, Mireia ;
Castellsague, Xavier ;
Clifford, Gary ;
Bruni, Laia ;
Munoz, Nubia ;
Bosch, F. Xavier .
LANCET INFECTIOUS DISEASES, 2007, 7 (07) :453-459